Drug eluting stents and beyond

Current Pharmaceutical Design

Volumn 14, Issue 21, 2008, Pages 2111-2120

  Rastogi, Ashish ^a   Stavchansky, Salomon ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Bare metal stents; Drug eluting stents; Late stent thrombosis; Polymers; Restenosis

Indexed keywords

ADHESIVE AGENT; ALLOY; ANTITHROMBOCYTIC AGENT; BIOADHESIVE; BIOCERAMICS; BIOLIMUS A9; BIOPOLYMER; CHROMIUM; COBALT; COLLAGEN TYPE 1; CURCUMIN; DOCETAXEL; EVEROLIMUS; HYALURONIC ACID; HYDROXYAPATITE; NANOPARTICLE; PACLITAXEL; PHOSPHORYLCHOLINE; POLYLACTIC ACID; RAPAMYCIN DERIVATIVE; RESVERATROL; TACROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANGIOPLASTY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BARE METAL STENT; BIOCOMPATIBILITY; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; DRUG ELUTING STENT; ENDOTHELIAZATION; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATION; LATE STENT THROMBOSIS; MAGNETIC NANOPARTICLE LOADED ENDOTHELIAL CELL; MATERIAL COATING; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROSTHESIS MATERIAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; STENT; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ATHEROSCLEROSIS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 52949154646     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785294573     Document Type: Review

References (154)

1. Doby T. History of cardiovascular catheterization. Clio Med 1977; 12(2-3): 185-8.
2. Fabian J, Bytesnik J, Belan A, Cerbak R, Endrys J, Kucera M, et al. History, present status and perspectives of interventional catheterization in cardiac and vascular diseases. Cas Lek Cesk 1984; 123(8):212-5.
3. Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J 1995; 129(1): 146-72.
4. Bourassa MG. The history of cardiac catheterization. Can J Cardiol 2005; 21(12): 1011-4.
5. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, et al. Results of Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002; 106(10): 1243-50.
6. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293(2): 165-71.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349(14): 1315-23.
8. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Eng J Med 2003; 348(16):1537-45.
9. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL). sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002; 106(15): 1949-56.
10. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16(2): 181-91.
11. Geerts AM, Colle I. Angiogenesis in portal hypertension: involvement in increased splanchnic blood flow and collaterals? Acta Clin Belg 2007; 62(5):271-5.
12. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002; 106(21): 2649-51.
13. Hoff HE, Geddes LA, McCrady JD. The contributions of the horse to knowledge of the heart and circulation. 1. Stephen Hales and the measurement of blood pressure. Conn Med 1965; 29(11): 795-800.
14. Buzzi A. Claude Bernard on cardiac catheterization. Am J Cardiol 1959; 4: 405-9.
15. Forssmann W. Sondierung des rechten Herzens. Klin Wochenschr 1929(8): 2085.
16. Cournand A, Riley RL, Breed ES, Baldwin ED, Richards DW, Lester MS, et al. Measurement of cardiac output in man using the technique of catheterization of the right auricle or ventricle. J Clin Invest 1945; 24(1): 106-16.
17. Sulek K. Nobel prize for Andre F. Cournand, Werner TO. Forssmann and Dickinson W. Richards in 1956 for the discovery related to heart catheterization and studies on pathological changes in the cardiovascular system. Wiad Lek 1969; 22(2):203-4.
18. Connolly JE. The development of coronary artery surgery: personal recollections. Tex Heart Inst J 2002; 29(1): 10-4.
19. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. description of a new technic and a preliminary report of its application. Circulation 1964; 30: 654-70.
20. Payne MM. Charles Theodore Dotter. The father of intervention, Tex Heart Inst J 2001; 28(1): 28-38.
21. Zdravkovic M, Zdravkovic D, Milic N, Milinic N, Dukanovic B, Zamaklar-Trifunovic D. Rene Favaloro-a surgeon who has changed the history of coronary disease. Med Pregl. 2006; 59(5-6): 281-5.
22. Hurst JW. The first coronary angioplasty as described by Andreas Gruentzig. Am J Cardiol 1986; 57(1): 185-6.
23. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006; 354(5): 483-95.
24. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Eng J Med 1987; 316(12): 701-6.
25. Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable intraluminal graft a preliminary study. Work in progress. Radiology 1985; 156(1):73-7.
26. Palmaz JC, Windeler SA, Garcia F, Tio FO, Sibbitt RR, Reuter SR. Atherosclerotic rabbit aortas: expandable intraluminal grafting. Radiology 1986; 160(3): 723-6.
27. Foutes I, Barrow D. From sirolimus to the Cypher stent: stages of the victory against restenosis. Ann Cardiol Angeiol (Paris) 2004; 53(Suppl 1): 3s-8s.
28. Sakamoto H, Ishikawa T, Mutoh M, Okada H, Tsurusaki T, Ohta M, et al. Effectiveness of a sirolimus-cluting stent (Cypher) for diffuse in-stent restenosis inside a barc metal stent. Int Heart J 2006; 47(5): 651-61.
29. DeJohn P. FDA approves Taxus stent; materials, managers cheer. Hosp Mater Manage 2004; 29(4): 1-9.
30. Suzuki Y, Ikeno F, Yeung AC. Drug-eluting stent strut distribution: a comparison between Cypher and Taxus by optical coherence tomography. J Invasive Cardiol 2006; 18(3): 111-4.
31. Shafiq N, Malhotra S, Pandhi P, Behl A, Sharma YP. Cypher versus Taxus: the stent war. Expert Opin Investig Drugs 2006; 15(12): 1537-44.
32. Aziz S, Morris JL, Perry RA. Late stent thrombosis associated with coronary aneurysm formation after sirolimus-eluting stent implantation. J Invasive Cardiol 2007; 19(4): E96-8.
33. Camenzind E. Treatment of in-stent restenosis-back to the future? N Engl J Med 2006; 355(20): 2149-51.
34. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115(11):1440-55
35. Pfisterer ME. The BASKET-LATE-Study. Basel stent cost-effectiveness trial-late thrombotic events trial. Herz 2006; 31(3): 259.
36. FDA. http://www.fda.gov/cdrh/news/091406.html. Accessed 23 December, 2007.
37. Kim HL, Park KW, Kwak JJ, Kim YS, Sir JJ, et al. Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs bare metal stent. Int J Cardiol 2008; 123(3): 353-4.
38. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356(10): 1009-19.
39. Steinberg DH, Waksman R. Drug-eluting stent thrombosis vs bare metal stent restenosis: finding the lesser of two evils. Am Heart Hosp J 2007; 5(3): 151-4.
40. Li JJ, Nie SP, Zhang CY, Gao Z, Zheng X, Guo YL. Is inflammation a contributor for coronary stent restenosis? Med Hypotheses 2007; 68(5): 945-51.
41. Golino P, Ambrosio G, Ragni M, Cirillo P, Esposito N, Willerson JT, et al. Inhibition of leucocyte and platelet adhesion reduces neointimal hyperplasia after arterial injury. Thromb Haemost 1997; 77(4): 783-8.
42. Sainani GS, Maru VG. The endothelial leukocyte adhesion molecule. Role in coronary artery disease. Acta Cardiol 2005; 60(5): 501-7.
43. Wang X, Feuerstein GZ, Clark RK, Yue TL. Enhanced leucocyte adhesion to interleukin-1 beta stimulated vascular smooth muscle cells is mainly through intercellular adhesion molecule-1. Cardiovasc Res 1994; 28(12): 1808-14.
44. Holmes DR, Jr. Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents. Rev Cardiovasc Med 2007,; 8(Suppl 1): S11-8.
45. Farb A, Boam AB. Stent thrombosis rectux-the FDA perspective. N Engl J Med 2007; 356(10): 984-7.
46. Buellesfeld L, Grube E. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts? Herz 2004; 29(2): 167-70.
47. Scabra-Gomes R. Percutaneous coronary interventions with drug eluting stents for diabetic patients. Heart 2006; 92(3): 410-9.
48. Lasave LI, Costa Ide R Jr, Abizaid AA, Feres F, Tanajura LF, Staico R, et al. A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (ZoMaxx) and the non-drug-eluting TriMaxx stent. J Invasive Cardiol 2007; 19(7): 303-8.
49. Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006; 66(4): 547-70.
50. Farb A, John M, Acampado E, Kolodgie FD, Prescott MY, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002; 106(18): 2379-84.
51. Waksman R, Pakala R, Baffour R, Hellinga D, Seabron R, Kolodgie F, et al. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. Cardiovasc Revasc Med 2006; 7(3): 179-84.
52. Patel JK, Kobashigawa JA. Everolimus: an immunosuppressive agent in transplantation. Expert Opin Pharmacother 2006; 7(10): 1347-55.
53. Grube E, Buellesfeld L. Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med 2004; 5(Suppl 2): S3-8.
54. Abbott V. http://www.abbottvascular.com/global/url/pressRelease/en_US/ 60.5:5/Press_Release_0434.htm Accessed 23 December, 2007.
55. Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 2006; 3(6): 731-41.
56. Costa R A, Lansky AJ, Abizaid A, Mueller R, Tsuchiya Y, Mori K, et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 2006; 98(4): 443-6.
57. Chevalier B. NOBORI I: Part 1:,A prospective, randomized trial of Biolimus A9 and paclitaxel-eluthig stents: 9-month clinical and angiographic follow-up. Transcatheter Cardiovascular Therapeutics Symposium 2006.
58. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara K Kohsaka M, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19(5) (Suppl 6): 4-8.
59. Gottschalk AR, Quintans J. Apoptosis in B lymphocytes: the WEHI-231 perspective. Immunol Cell Biol 1995; 73(1): 8-16.
60. Grube E, Buellesfeld L. Rapamycin analogs for stent-based local drug delivery, Everolimus- and tacrolimus-eluting stents. Herz 2004; 29(2): 162-6.
61. Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A, et al. Particle debris ftom a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of resteriosis. Catheter Cardiovasc Interv 2005; 64(1): 85-90.
62. Margolis J, McDonald J, Heuser R, Klinke P, Waksman R, Virmani R, et al. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. Clin Cardiol 2007; 30(4): 165-170.
63. Green M R, Manikhas GM, Orlov S, Afanasyev B, Makhsou AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17(8): 1263-8.
64. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36(2):99-114,
65. Lucatelli C, Viton F, Gimbert Y, Greene AE. Synthesis of C-3′ methyl taxotere (docetaxel). J Org Chem 2002; 67(26): 9468-70.
66. Yasuda S, Noguchi T, Gohda M, Arai T, Tsutsui N, Nakayama Y, et al. Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia, in a balloon-injured rabbit iliac artery model. Cardiovasc Res 2002; 53(2): 481-6.
67. Gundersen GGaC, Tiffani A. Microtubule and signal transduction. Curr Opin Cell Biol 1999; 11: 81-94.
68. Silvestrini R, Zaffaroni N, Orlandi L, Oriana S. In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer. Stern Cells 1993; 11(6): 528-35.
69. Huang M T, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 1994; 54(22): 5841-47.
70. Dorai T, Aggarwal BB. Role of chemopteventive agents in cancer therapy. Cancer Lett 2004; 215(2): 129-40.
71. Gupta KK, Bharne SS, Rathinasamy K, Naik NR, Panda D. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J 2006; 273(23): 5320-32.
72. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995; 94(1): 79-83.
73. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JP, Das PK. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003; 139(2): 209-18.
74. Docherty R, Fu MM, Tsai M. Resveratrol selectively inhibits Neisseria gonorrhoeae and Neisseria meningitidis. J Antimicrob Chemother 2001; 47(2): 243-4.
75. Kopp P. Resveratrol, a phytoestrogen found in red wine: A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 1998; 139(6): 619-20.
76. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and prooxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007; 35(Pt 5): 1156-60.
77. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 1999; 43(3): 145-55.
78. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007; 30(1-2): 1-6.
79. Kasdallah-Grissa A, Mornagui B, Aouani E, et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 2007; 80(11): 1033-9.
80. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006; 72(11): 1439-52.
81. Mrjoyan ZH, Fujise K. Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/ CIP1) pathway. Biochem Biophys Res Commun 2003; 311(2):546-52.
82. Olas B, Wachowicz B. Resveratrol, a phenolic antioxidant with effects on blood platelet functions. Platelets 2005; 16(5):251-60.
83. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995; 235(2): 207-19.
84. Poussier B, Cordova AC, Becquemin JP, Sumpio BE. Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vasc Surg 2005; 42(6): 1190-7.
85. Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol 2005; 95(1): 8-12.
86. Gorman I. Characteristics of metals used in implants. J Endourol 1997; 11(6): 383-9.
87. Zupancic R, Legat A, Funduk N. Tensile strength and corrosion resistance of brazed and laser-welded cobalt-chromium alloy joints. J Prosthet Dent 2006; 96(4): 273-82.
88. Mirkovic N. Mechanical properties of metal-ceramic systems from nickel-chromium and cobalt-chromium alloys, Vojnosanit Pregl 2007; 64(4): 241-5.
89. Roach M. Base metal alloys used for dental restorations and implants. Dent Clin North Am 2007; 51(3): 603-27.
90. Schievano S, Petrini L, Migliavacca F, Coats L, Nordmeyer J, Lurz P, et al. Finite element analysis of stent deployment: understanding stent fracture in percutaneous pulmonary valve implantation. J Interv Cardiol 2007; 20(6): 546-54.
91. Sanada J, Matsui O, Terayama N, Kobayashi S, Minami T, Kurozimi M, et al. Clinical application of a curved nitinol stent-graft for thoracic aortic aneurysms. J Endovasc Ther 2003; 10(1): 20-8.
92. Lim IA, Biocompatibility of stent materials. MURJ 2004; 11: 33-6.
93. Cloft HJ, Kallmes DF, Lin HB, Li ST, Marx WF, Hudson SB, et al. Bovine type I collagen as an endovascular stent-graft material: bio-compatibility study in rabbits. Radiology 2000; 214(2): 557-62.
94. Medscape. http://www.medscape.com/viewarticle/555391. Accessed 25 June, 2008.
95. Polyak B, Fishbein I, Chorny M, Alferiev I, Williams D, Yellen B, et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci USA 2008; 105(2): 698-703.
96. LeGeros RZ, Lin S, Rohanizadeh R, Mijares D, LeGeros JP. Biphasic calcium phosphate bioceramics: preparation, properties and applications. J Mater Sci Mater Med 2003; 14(3): 201-9.
97. de Oliveira RS, Brigato R, Madureira JF, Cruz AA, de Mello Filho FV, Alonso N, et al. Reconstruction of a large complex skull defect in a child: a case report and literature review. Childs Nerv Syst 2007; 23(10): 1097-102.
98. Mastrogiacomo M, Corsi A, Francioso E, Di Comite M, Monetti F, Scaglione S, et al. Reconstruction of extensive long bone defects in sheep using resorbable bioceramics based on silicon stabilized tri-calcium phosphate. Tissue Eng 2006; 12(5); 1261-73.
99. Hiu-Yan Y, Ling Q, Kwong-Man L, Ming Z, Kwok-Sui L, Chunyiu CJ. Novel approach for quantification of porosity for biomaterial implants using microcomputed tomography (microCT). J Biomed Mater Res B Appl Biomater 2005; 75(2): 234-42.
100. Sun JS, Tsuang YH, Yao CH, Liu HC, Lin FH, Hang YS. Effects of calcium phosphate bioceramics on skeletal muscle cells. J Biomed Mater Res 1997; 34(2): 227-33.
101. Lemons JE. Ceramics: past, present, and future. Bone 1996; 19(1 Suppl): 121S-8S.
102. Adamopoulos O, Papadopoulos T. Nanostructured bioceramics for maxillofacial applications. J Mater Sci Mater Med 2007; 18(8): 1587-97.
103. Marti A. Inert bioceramics (A1203, ZrO2) for medical application. Injury 2000; 31(Suppl 4): 33-6.
104. Pietak AM, Reid JW, Stott MJ, Sayer M. Silicon substitution in the calcium phosphate bioceramics. Biomaterials 2007; 28(28): 4023-32.
105. Traykova T, Aparicio C, Ginebra MP, Planell JA. Bioceramics as nanomaterials. Nanomed 2006; 1(1): 91-106.
106. Vallet-Regi M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed Engl 2007; 46(40):7548-58.
107. Willmann G. Standardization of zirconia ceramics for hip endoprostheses. Biomed Tech (Berl) 1997; 42(12): 342-6.
108. Mizushima Y, Ikoma T, Tanaka J, Hoshi K, Ishihara T, Ogawa Y, et al. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. J Control Release 2006; 110(2):260-5.
109. Costantino PD, Friedman CD, Jones K, Chow LC, Pelzer HI, Sisson GA, Sr. Hydroxyapatite cement. I. Basic chemistry and histologic properties. Arch Otolaryngol Head Neck Surg 1991; 117(4): 379-84.
110. Allegrini S Jr, Rumpel E, Kauschke E, Fanghanel J, Konig B, Jr. Hydroxyapatite grafting promotes new bone formation and osseointegration of smooth titanium implants. Ann Anat 2006; 188(2): 143-51.
111. Wen CE, Xu W, hu WY, Hodgson PD. Hydroxyapatite/titania solgel coatings on titanium-zirconium alloy for biomedical applications. Acta Biomater 2007; 3(3): 403-10.
112. Underwood PA, Bennett FA. The effect of extracellular matrix molecules on the in vitro behavior of bovine endothelial cells. Exp Cell Res 1993; 205(2): 311-9.
113. Xiao L, Shi D. Role of pre-coating in artificial vessel endothelialization. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2005; 19(4): 270-3.
114. Patel HJ, Su SH, Patterson C, Nguyen KT. A combined strategy to reduce restenosis for vascular tissue engineering applications. Biotechnol Prog 2006; 22(1): 38-44.
115. van den Beucken JJ, Walboomers XF, Nillesen ST, Vos MR, Sommerdijk NA, van Kuppevelt TH, et al. In vitro and in vivo effects of deoxyribonucleic acid-based coatings funtionalized with vascular endothelial growth factor. Tissue Eng 2007; 13(4): 711-20.
116. Lerouge S, Major A, Girault-Lauriault PL, Raymond MA, Laplante P, Soulez G, et al. Nitrogen-rich coatings for promoting healing around stent-grafts after endovascular aneurysm repair. Biomaterials 2007; 28(6): 1209-17.
117. Charbonneau C, Gautrot JE, Hebert MJ, Zhu XX, Lerouge S. Chondroitin4-sulfate: a bioactive macromolecule to foster vascular healing around stent-grafts after endovascular aneurysm repair. Macromol Biosci 2007; 7(5): 746-52.
118. CSIRO B. http://www.bio.csiro.au/Projects/Bioadhesive.htm. Accessed 23 December, 2007.
119. Whittington ID, Cribb BW. Adhesive secretions in the Platyhelminthes. Adv Parasitol 2001; 48: 101-224.
120. DeMoor S, Waite JH, Jangoux M, Flammang P. Characterization of the adhesive from euvierian tubules of the sea cucumber Holothuria forskali (Fchinodermata, Holothuroidea). Mar Biotechnol (NY) 2003; 5(0); 45-57.
121. Waite JR. Mussel glue from Mytilus californianus Conrad: a comparative study. J Comp Physiol [B] 1986; 156(4): 491-6.
122. Monahan J, Wilker JJ. Cross-linking the protein precursor of marine mussel adhesives: bulk measurements and reagents for curing. Langmuir 2004; 20(9): 3724-9.
123. Lin Q, Gourdon D, Sun C, Holten-Andersen N, Anderson TH, Waite J, et al. Adhesion mechanisms of the mussel foot proteins mfp-1 and mfp-3. Proc Natl Acad Sci USA 2007; 104(10): 3782-6.
124. Deacon MP, Davis SS, White R, Waite JH, Harding SE. Monomeric behaviour of Mytilus edulis (mussel) glue protein in dilute solution. Biochem Soc Trans 1997; 25(3): 422S.
125. CSIRO B. http://www.esiro.au/pubgenesite/research/ human_health_nutrition/frogGlue.htm. Accessed 23 December, 2007.
126. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997; 242(1):27-33.
127. Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992; 6(7): 2397-404.
128. Ferruti P, Bianchi S, Ranucci E, Chiellini F, Caruso V. Novel poly(amido-amine)-based hydrogels as scaffolds for tissue engineering. Macromol Biosci 2005; 5(7): 613-22.
129. Rodgers LS, Lalani S, Hardy KM, Xiang, X, Broka D, Antin PB, et al. Depolymerized hyaluronan induces vascular endothelial growth factor, a negative regulator of developmental epithelial-tomesenchymal transformation. Circ Res 2006; 99(6): 583-9.
130. Verheye S, Markou CP, Salame MY, Wan B, King SB, 3rd, Robinson KA, et al. Reduced thrombus formation by hyaluronic acid coating of endovascular devices. Arterioscler Thromb Vasc Biol 2000; 20(4): 1168-72.
131. Heublein B, Evagorou EG, Rohde R, Ohse S, Meliss RR, Barlach S, et al. Polymerized degradable hyaluronan - a platform for stent coating with inherent inhibitory effects on neointimal formation in a porcine coronary model. Int J Artif Organs 2002; 25(12): 1166-73.
132. Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) cluting stents. Adv Drug Deliv Rev 2006; 58(3): 437-46.
133. Lewis AL, Stratford PW. Phosphorylcholine-coated stents. J Long Term Eff Med Implants 2002; 12(4): 231-50.
134. Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J Invasive Cardiol 2001; 13(3): 193-201.
135. Whelan DM, van der Giessen WJ, Krabbendam, SC, van Vliet EA, Verdouw PD, Serruys PW, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83(3): 338-45.
136. Campbell EJ, O'Byrne V, Stratford PW, Quirk I, Vick TA, Wiles MC, et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J 1994; 40(3): M853-7.
137. Boland JL, Corbeij HA, Van Der Giessen W, Seabra-Gomes R, Suryapranata, H, Wijns W, et al. Multicenter evaluation of the phosphorylcholine-coated biodivYsio stent in short de novo coronary lesions: The SOPHOS study. Int J Cardiovasc Intervent 2000; 3(4): 215-25.
138. Galli M, Sommariva L, Prati F, Zerboni S, Politi A, Bonatti R, et al. Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction. Catheter Cardiovasc Interv 2001; 53(1): 182-7.
139. Medtronic I. http://wwwp.medtronic.com/Newsroom/NewsRelease Details.do?itemld=1165584506560&lang=en_US. Accessed 20 November, 2007.
140. FDA. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01787.html. Accessed 1 February, 2008.
141. Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, et al. Zotarolimus-cluting, stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007; 100(8B): 45M-55M.
142. Mehta RH, Leon MB, Sketch MH, Jr. The relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. Am J Cardiol 2007; 100(8B): 62M-70.
143. Sakurai R, Bonneau HN, Honda Y, Fitzgerald PJ. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am J Cardiol 2007; 100(8B): 71M-6.
144. Jain AK, Meredith IT, Lotan C, Rothman MT, Pateraki S. Realworld safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry. Am J Cardiol 2007; 100(8B): 77M-83.
145. PTCA. http://www.ptoa.org/news/2007/1129_ABBOTT.html. Acce ssed 20 November, 2007.
146. Abbott. http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/ Press_Release_0499.htm. Accessed 25 December, 2007.
147. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, et al. A randomised comparison of an everolimus-elating coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. Eurointervention 2006; 2(3): 286-94.
148. PTCA. http://www.ptca.org/newscenter.html?http://www.ptca.org/news/ 2007/0601.html. Accessed 20 November, 2007.
149. PTCA. http://www.ptca.org/newscenter.html?http://www.ptea.org/news/ 2006/1004.html. Accessed 20 November, 2007.
150. Conor M. http://www.conormed.com/tech/index.html. Accessed 23 December, 2007.
151. Heart. http://www.theheart.org/article/789091.do. Accessed 20 November, 2007.
152. PTCA. http://www.ptca.org/nv/desnews.html. Accessed 20 November, 2007.
153. Hensley S. Stent wars. Guidant beats back market leader Johnson & Johnson with new device. Mod Healthe 1998; 28(2): 49.
154. Meier B. Drug-eluting stents: the next chapter of the coronary stent saga. Am Heart Hosp J 2007; 5(3): 173-6.